SCHEMBL24975342

SCHEMBL24975342

CCC(=O)Nc1ccc(-c2ccc(C(=O)NCc3cccnc3)cn2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 6/20 0.61
▸ ALDH1A1 P00352 3/20 0.61
▸ LMNA P02545 5/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ KMT2A Q03164 4/20 0.57
▸ MEN1 O00255 3/20 0.57
▸ HPGDS O60760 1/20 0.57
▸ MAPK1 P28482 2/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ NCOA1 Q15788 1/20 0.54
▸ NCOA3 Q9Y6Q9 1/20 0.54
▸ TSHR P16473 1/20 0.53
▸ MAPT P10636 2/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ NAMPT P43490 1/20 0.52
▸ POLB P06746 1/20 0.51
▸ GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29801153 1.00 HTT (0.61) HTTALDH1A1LMNANPSR1KMT2A
SCHEMBL24975354 0.90 HTT (0.77) HTTALDH1A1LMNANPSR1KMT2A
SCHEMBL29996180 0.89 HTT (0.72) HTTALDH1A1LMNANPSR1KMT2A
SCHEMBL23063861 0.89 HTT (0.72) HTTALDH1A1LMNANPSR1KMT2A
SCHEMBL29801317 0.84 HTT (0.58) HTTALDH1A1LMNANPSR1KMT2A
SCHEMBL24976313 0.84 HTT (0.58) HTTALDH1A1LMNANPSR1KMT2A
SCHEMBL29801122 0.83 KMT2A (0.66) HTTALDH1A1LMNAKMT2AMEN1
SCHEMBL24975530 0.83 HPGDS (0.64) HTTALDH1A1LMNAKMT2AHPGDS
SCHEMBL24975558 0.83 KMT2A (0.66) HTTALDH1A1LMNAKMT2AMEN1
SCHEMBL29801099 0.83 HPGDS (0.64) HTTALDH1A1LMNAKMT2AHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2023-01-26 — — US disclosed
CN-114929672-A Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, KIT, GLI1 HTT 991/4885ALDH1A1 23/4885LMNA 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback